Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$1.6bn ARMO Buy Gives Lilly Its Most Advanced Immuno-Oncology Asset

Executive Summary

Eli Lilly & Co. did not rush into the immuno-oncology game like its big pharma peers, but the acquisition of newly public ARMO gives the company its most advanced IO asset via external innovation – an increased focus for Lilly's portfolio.

Advertisement

Related Content

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
IPO Update: Returns Sag As Seven More Biopharmas Go Public In September
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Biopharma Quarterly Dealmaking Statistics, Q2 2018
IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns
Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies
Immunocore attracts Lilly in co-co deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel